Medical board reviews petition on cannabis use for kidney stone pain relief

A significant discussion unfolded during the Board of Physicians meeting on June 30, 2025, regarding the potential inclusion of medical marijuana for treating medullary sponge kidney disease. This rare congenital disorder, characterized by the formation of small cysts in the kidneys, can lead to painful conditions such as urinary tract infections and kidney stones.

The board reviewed a petition advocating for the use of cannabinoids to alleviate pain associated with kidney stones, a condition known for its acute and chronic discomfort. While the petitioner presented a study suggesting a possible reduction in kidney stone incidence among marijuana users, board members expressed skepticism about the strength of the evidence.

One board member highlighted the limited research available, noting that only two relevant studies were found in scientific literature. The studies did not provide robust support for the effectiveness of cannabinoids in treating kidney stone pain or reducing the frequency of stones. The board member emphasized that the existing data primarily focused on male populations and lacked specific insights into patients with medullary sponge kidney disease.

The discussion underscored the need for more comprehensive research before making any decisions on the petition. The board concluded that while the condition is significant and painful, the current evidence does not warrant the approval of medical marijuana for this specific use. Further studies could provide clarity and potentially lead to more informed decisions in the future.